CRBP241220C2500
- 17.40
- 0.000.00%
Corbus Pharmaceuticals Newsroom
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $65
Corbus Pharmaceuticals (CRBP) Receives a Buy From RBC Capital
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $75
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment With a Buy Rating
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $60
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Corbus Pharmaceuticals (CRBP) Receives a Buy From Mizuho Securities
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $74
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
Buy Rating Affirmed for Corbus Pharmaceuticals on CRB-913's Potential and Holistic Pipeline Valuation
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $88
Corbus Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Corbus Pharmaceuticals Price Target Maintained With a $74.00/Share by Mizuho